Alector, Abbvie partner on therapies for Alzheimer's

Development of new Alzheimer’s disease treatments is the focus of separate collaboration agreements announced today by AbbVie and Biogen.

AbbVie and Alector said they plan to develop and commercialize therapies to treat Alzheimer's and other neurodegenerative disorders using the latter’s immuno-neurology drug discovery tech platform, through a collaboration that could generate up to $225 million for Alector.

Alector’s platform is designed to fight Alzheimer’s and other neurodegenerative diseases by harnessing the immune system, specifically the microglia. The microglia, according to Alector, is where a large fraction of gene variants is expressed that increase or decrease the chance of developing neuro-degenerative disease, as identified in genome-wide association studies (GWAS).